Logo

Vertex's Kaftrio + Ivacaftor Receive the EC's Approval to Treat Cystic Fibrosis in People Aged 12 Years and Older

Share this

Vertex's Kaftrio + Ivacaftor Receive the EC's Approval to Treat Cystic Fibrosis in People Aged 12 Years and Older

Shots:

  • The EC has granted MAA to Kaftrio (ivacaftor/tezacaftor/lumacaftor) + ivacaftor (150mg) to treat people with CF aged ≥12yrs. with one F508del mutation and one minimal function mutation (F/MF)- or two F508del mutations (F/F) in the CFTR gene
  • The MAA is based on two P-III studies i.e. a 24wks. study in 403 people with one F508del mutation and one F/MF & a 4wks. study in 107 people with two F508del mutations (F/F). The studies demonstrated improvements in lung function (1EPs) and all 2EPs and were generally well-tolerated in both studies
  • Kaftrio is designed to increase the quantity and function of the F508del-CFTR protein at the cell surface

­ Ref: PRNewswire | Image: Vertex

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions